Robert W. Baird Lowers ICON Public (NASDAQ:ICLR) to Neutral

Robert W. Baird cut shares of ICON Public (NASDAQ:ICLR) from an outperform rating to a neutral rating in a report released on Thursday, MarketBeat reports. They currently have $340.00 price objective on the medical research company’s stock.

A number of other equities research analysts also recently commented on the stock. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Truist Financial dropped their price target on ICON Public from $383.00 to $363.00 and set a “buy” rating on the stock in a research note on Monday, October 14th. StockNews.com cut ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Evercore ISI dropped their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Barclays lowered their target price on ICON Public from $350.00 to $330.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 15th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $310.45.

ICON Public Trading Down 0.6 %

NASDAQ ICLR opened at $220.47 on Thursday. ICON Public has a 12 month low of $220.01 and a 12 month high of $347.72. The stock’s fifty day moving average price is $297.75 and its 200-day moving average price is $310.20. The stock has a market cap of $18.19 billion, a P/E ratio of 25.70, a P/E/G ratio of 1.35 and a beta of 1.22. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the business posted $3.10 earnings per share. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities analysts forecast that ICON Public will post 14.53 EPS for the current fiscal year.

Hedge Funds Weigh In On ICON Public

Several institutional investors have recently bought and sold shares of ICLR. Arkadios Wealth Advisors purchased a new position in ICON Public in the first quarter worth about $247,000. Whittier Trust Co. increased its position in shares of ICON Public by 21.9% during the 1st quarter. Whittier Trust Co. now owns 3,295 shares of the medical research company’s stock valued at $1,107,000 after purchasing an additional 593 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in ICON Public by 410.8% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock valued at $63,000 after buying an additional 152 shares during the period. First National Bank of Hutchinson raised its holdings in ICON Public by 5.7% during the 1st quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock valued at $381,000 after buying an additional 61 shares during the period. Finally, Motco lifted its position in ICON Public by 1.5% in the first quarter. Motco now owns 3,882 shares of the medical research company’s stock worth $1,304,000 after buying an additional 59 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.